TABLE 3.
Breast cancer subtypes
| Non‐invasive histological types | |
|---|---|
| Adenocarcinoma (99.9%) | Ductal carcinoma in situ (DCIS) (80.1%) |
| Lobular carcinoma in situ (LCIS) (15.9%) | |
| Intraductal and lobular in situ carcinoma (3.4%) | |
| Other adenocarcinomas (0.5%) | |
| Other in situ histologies (0.1%) | |
| Invasive histological types a | ||
|---|---|---|
| Carcinoma (99.5%) | Adenocarcinoma (97.7%) | Infiltrating duct carcinoma (72.4%) |
| Lobular carcinoma, NOS (9.9%) | ||
| Mixed NST and special subtypes (9.7%) | ||
| Mucinous adenocarcinoma (1.8%) | ||
| Other adenocarcinomas (1.5%) | ||
| Papillary adenocarcinoma (0.8%) | ||
| Adenocarcinoma NOS (0.6%) | ||
| Tubular adenocarcinoma (0.5%) | ||
| Paget disease (0.3%) | ||
| Inflammatory adenocarcinoma (0.2%) | ||
| Unspecified, carcinoma, NOS (0.9%) | ||
| Other specific carcinoma (0.8%) | ||
| Epidermoid carcinoma (cca. 0.2%) | ||
| Sarcoma and soft tissue tumours (0.1%) | Hemangiosarcomas (cca. 0.1%) | |
| Other sarcomas (cca. 0.1%) | ||
| Other specific types (0.2%) | Phyllodes tumour, malignant (0.2%) | |
| Other (0.0%) | ||
| Unspecified (0.2%) | ||
| Intrinsic subtype | IHC status | Grade | Prevalence |
|---|---|---|---|
| Luminal type A | (ER+, PR+), HER2‐, Ki‐67‐(<15%) | 1/2 | 23.7% |
| Luminal type B |
(ER+, PR+), HER2‐, Ki‐67+(>15%) (ER+, PR‐), HER2‐, Ki‐67+(>15%) |
2/3 |
38.8% 14% |
| HER2 | (ER‐, PR‐), HER2+ | 2/3 | 11.2% |
| Basal | (ER‐, PR‐), HER2‐, basal markers+ | 3 | 12.3% |
| Normal like | (ER+, PR+), HER2‐, Ki‐67‐ (<15%) | 1/2/3 | 7.8% |